Prenatal CFTR modulator therapy for fetal cystic fibrosis: Emerging evidence, clinical considerations, and future directions. (PubMed, Pregnancy (Hoboken)) - Oct 2, 2026 - "The advent of CFTR modulator therapies (CFTR modulator)-most notably elexacaftor/tezacaftor/ivacaftor (ETI), approved for children and adults with CF who carry responsive variants, and the recently approved vanzacaftor/tezacaftor/deutivacaftor (VTD), currently indicated for older pediatric and adult populations-has transformed long-term health outcomes and substantially increased the number of pregnancies among individuals with CF. While continuation for maternal CF is supported by available evidence (although not label-approved), fetal-indication use remains investigational. Robust counseling, interdisciplinary coordination, and structured monitoring are essential, alongside ongoing research to define therapeutic windows, safety, and long-term outcomes."
Journal • Review • Cataract • Cystic Fibrosis • Genetic Disorders • Immunology • Ophthalmology • Pediatrics • Pulmonary Disease • Respiratory Diseases
|
|
Aaron T Trimble; Alireza A Shamshirsaz; Angela Metcalf; Carmen Luna-Paredes; Edith T Zemanick; Elizabeth B Burgener; Hiba J Mustafa; Isabelle Sermet-Gaudelus; Jennifer L Taylor-Cousar; Jordana E Hoppe; Michael V Zaretsky; Ramen H Chmait; Scott D Sagel; Stacey L Martiniano; Sylvia E Szentpetery; Yair J Blumenfeld
|